OrSense's Non-Invasive Glucose Sensor Achieves Accurate Performance In Acute Care Setting

New Ziona, Israel - Results of a study presented by Prof. Pierre Singer at the 26th International Symposium on Intensive Care and Emergency Medicine (ISICEM) indicate that the continuous non-invasive glucose monitoring system developed by OrSense Ltd. accurately measures levels of glucose in an acute care setting.

Tight glycemic control has been shown to benefit intensive care patients. Hyperglycemia, elevated blood glucose levels, and insulin resistance are common findings in critically ill patients, even those without diabetes. Recently it was shown that preventing hyperglycemia with insulin substantially improves outcome of critical illness and has been shown to reduce mortality in intensive care units (ICU). Additionally, maintenance of normal glucose levels may shorten the ICU stay duration, which significantly reduces healthcare expense. Currently, monitoring methods can not fulfill the need for continuous glucose monitoring in order to safely implement tight glucose control protocols.

"The ability to maintain normal levels of glucose in acute care patients is currently one of the most important goals of intensive care units," said Prof. Singer, Rabin Medical Center, Petah-Tikva, Israel and the principal investigator of the study. "Based on the study's conclusions, we believe that OrSense's non-invasive glucose monitoring system potentially could be used for continuous, accurate, safe and easy to use glucose evaluation for intensive care units. Consequently, it will improve patient care and survival, as well as reduce staff workload," Prof. Singer concluded.

Lior D. Ma'ayan, Chief Executive Office, OrSense said, "The results of this study are indicative of OrSense's capabilities in delivering breakthrough non-invasive glucose monitoring technology. We are committed to answer the need for non-invasive monitoring solution for home glucose testing as well as in hospital settings."

The study is one arm out of three studies that were carried out on a total of 30 patients in three different hospitals in Israel. This specific study was conducted on 6 patients, three females and three males, between the ages of 44 and 88-years old, in the intensive care unit of the Rabin Medical Center. The study was designed to evaluate the feasibility of the OrSense's devise for non-invasive continuous glucose monitoring in critically ill patients in the ICU.

In the study, the OrSense sensor performed non-invasive continuous measurements for up to 24 hours. The results were compared to measurements obtained by conventional invasive methods. The range of the glucose levels measured in the study was 64-247 mg/dl. The resulting Median Relative Absolute Difference was 11.5%, and the Median Absolute Difference was 18 mg/dl. A Clarke error grid analysis showed that 100% of measurements fell within the clinically accurate and acceptable zones A and B.

SOURCE: OrSense Ltd.